Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

Gallwitz, Baptist, Guzman, Juan, Dotta, Francesco, Guerci, Bruno, Simó, Rafael, Basson, Bruce R, Festa, Andreas, Kiljański, Jacek, Sapin, Hélène, Trautmann, Michael, Schernthaner, Guntram·2012·The Lancet

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)60479-6

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 14

  1. Tahrani, 2011, Management of type 2 diabetes: new and future developments in treatment, Lancet, 378, 182, 10.1016/S0140-6736(11)60207-9 · DOI · Paper page
  2. Bergenstal, 2010, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
  3. Visbøll, 2009, The effects of glucagon-like peptide-1 on the beta cell, Diabetes Obes Metab, 11, 11, 10.1111/j.1463-1326.2009.01073.x · DOI
  4. Kazda, 2009, The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics, Diabetes Obes Metab, 11, 1131, 10.1111/j.1463-1326.2009.01091.x · DOI
  5. Buse, 2009, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 374, 39, 10.1016/S0140-6736(09)60659-0 · DOI · Paper page
  6. Garber, 2011, Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvememnts in galycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes, Diabetes Obes Metab, 13, 348, 10.1111/j.1463-1326.2010.01356.x · DOI · Paper page
  7. Seino, 2010, Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes, Curr Med Res Opin, 26, 1013, 10.1185/03007991003672551 · DOI
  8. Malone, 2004, Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy, Clin Ther, 26, 2034, 10.1016/j.clinthera.2004.12.015 · DOI · Paper page
  9. Derosa, 2009, Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes, Diabetes Obes Metab, 11, 1091, 10.1111/j.1463-1326.2009.01087.x · DOI
  10. Bergenstal, 2010, Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications, Am J Med, 123, 374.e9, 10.1016/j.amjmed.2009.07.017 · DOI
  11. Aguilar, 2011, Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success, Clin Ther, 33, 408, 10.1016/j.clinthera.2011.04.008 · DOI
  12. Pratley, 2010, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial, Lancet, 375, 1447, 10.1016/S0140-6736(10)60307-8 · DOI · Paper page
  13. Matthew, 2010, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study, Diabetes Obes Metab, 12, 780, 10.1111/j.1463-1326.2010.01233.x · DOI · Paper page
  14. Ferrannini, 2009, Fifty-two week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin therapy, Diabetes Obes Metab, 11, 157, 10.1111/j.1463-1326.2008.00994.x · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., & Schernthaner, G.
Venue
The Lancet
Publisher
Elsevier BV
Published
2012-06
Volume
379
Issue
9833
Pages
2270-2278
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2124977666
Cited by
159
References
16
FWCI
15.42
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(12)60479-6
The paper
Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., & Schernthaner, G. (2012). Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(12)60479-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.